- Email: [email protected]
Information for category 1 CME credit
T HE J OURNAL OF
Allergy Clinical Immunology AND
INFORMATION FOR CATEGORY 1 CME CREDIT Credit can now be obtained, free for a limited time, by reading the review articles in this issue. Please note the following instructions. Method of Physician Participation in Learning Process: The core material for these activities can be read in this issue of the Journal or online at the JACI Web site: www.jacionline.org. The accompanying tests may only be submitted online at www.jacionline.org. Fax or other copies will not be accepted. Date of Original Release: January 2008. Credit may be obtained for these courses until December 31, 2010. Copyright Statement: Copyright Ó 2008-2010. All rights reserved. Overall Purpose/Goal: To provide excellent reviews on key aspects of allergic disease to those who research, treat, or manage allergic disease. Target Audience: Physicians and researchers within the field of allergic disease. Accreditation/Provider Statements and Credit Designation: The American Academy of Allergy, Asthma & Immunology (AAAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The AAAAI designates these educational activities for a maximum of 1 AMA PRA Category 1 CreditÔ. Physicians should only claim credit commensurate with the extent of their participation in the activity.
CME article
CME article
‘‘Targeting TNF-a: A novel therapeutic approach for asthma’’ (page 5)
‘‘B cell–directed therapies for autoimmune disease and correlates of disease response and relapse’’ (page 13)
List of Design Committee Members: Authors: Christopher Brightling, PhD, MRCP, Mike Berry, MD, MRCP, and Yassine Amrani, PhD Activity Objectives 1. To acknowledge the importance of the heterogeneity of asthma and the complexity of targeted therapies. 2. To understand the biology of TNF-a and its role in refractory asthma and airway hyperresponsiveness. 3. To review the current data on clinical trials involving anti– TNF-a therapy in asthma. 4. To discuss the risk-benefit profile of utilizing biologic agents to modulate severe disease. Recognition of Commercial Support: This CME activity has not received external commercial support. Disclosure of Significant Relationships with Relevant Commercial Companies/Organizations: Christopher Brightling has consulting arrangements with Cambridge Antibody Technology, GlaxoSmithKline, AstraZeneca, Pfizer, Roche, and Piramed; owns stock in Leicester AIR; has received grant support from AstraZeneca, Cambridge Antibody Technology, and GlaxoSmithKline; and is on the speakers’ bureau for AstraZeneca and GlaxoSmithKline. Yassine Amrani has received grant support from Centocor and the National Institutes of Health. Mike Berry has declared that he has no signficant relationships to disclose.
List of Design Committee Members: Authors: Marc C. Levesque, MD, PhD, and E. William St. Clair, MD Activity Objectives 1. To understand the rationale for B cell–targeted therapy in autoimmune diseases. 2. To understand the development and differentiation of B cell lineage. 3. To understand the mechanisms of action of B cell–directed antibodies. Recognition of Commercial Support: This CME activity has not received external commercial support. Disclosure of Significant Relationships with Relevant Commercial Companies/Organizations: Marc C. Levesque has consulting arrangements with Genentech; has received research support from the National Institutes of Health, Genentech, and Amgen; has served as an expert witness for Merck; and has served as a member of the Arthritis Foundation. E. William St. Clair has consulting arrangements with Biogen Idec, Genentech, Bristol Myers Squibb, Novartis, Human Genome Sciences, Medimmune, and Synovex; has received research support from the National Institutes of Health, Genentech, and Amgen; and has been a part of ACR Research and Education Board of Directors.
30A January 2008
J ALLERGY CLIN IMMUNOL
Allergy Clinical Immunology AND
INFORMATION FOR CATEGORY 1 CME CREDIT Credit can now be obtained, free for a limited time, by reading the review articles in this issue. Please note the following instructions. Method of Physician Participation in Learning Process: The core material for these activities can be read in this issue of the Journal or online at the JACI Web site: www.jacionline.org. The accompanying tests may only be submitted online at www.jacionline.org. Fax or other copies will not be accepted. Date of Original Release: January 2008. Credit may be obtained for these courses until December 31, 2010. Copyright Statement: Copyright Ó 2008-2010. All rights reserved. Overall Purpose/Goal: To provide excellent reviews on key aspects of allergic disease to those who research, treat, or manage allergic disease. Target Audience: Physicians and researchers within the field of allergic disease. Accreditation/Provider Statements and Credit Designation: The American Academy of Allergy, Asthma & Immunology (AAAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The AAAAI designates these educational activities for a maximum of 1 AMA PRA Category 1 CreditÔ. Physicians should only claim credit commensurate with the extent of their participation in the activity.
CME article
CME article
‘‘Targeting TNF-a: A novel therapeutic approach for asthma’’ (page 5)
‘‘B cell–directed therapies for autoimmune disease and correlates of disease response and relapse’’ (page 13)
List of Design Committee Members: Authors: Christopher Brightling, PhD, MRCP, Mike Berry, MD, MRCP, and Yassine Amrani, PhD Activity Objectives 1. To acknowledge the importance of the heterogeneity of asthma and the complexity of targeted therapies. 2. To understand the biology of TNF-a and its role in refractory asthma and airway hyperresponsiveness. 3. To review the current data on clinical trials involving anti– TNF-a therapy in asthma. 4. To discuss the risk-benefit profile of utilizing biologic agents to modulate severe disease. Recognition of Commercial Support: This CME activity has not received external commercial support. Disclosure of Significant Relationships with Relevant Commercial Companies/Organizations: Christopher Brightling has consulting arrangements with Cambridge Antibody Technology, GlaxoSmithKline, AstraZeneca, Pfizer, Roche, and Piramed; owns stock in Leicester AIR; has received grant support from AstraZeneca, Cambridge Antibody Technology, and GlaxoSmithKline; and is on the speakers’ bureau for AstraZeneca and GlaxoSmithKline. Yassine Amrani has received grant support from Centocor and the National Institutes of Health. Mike Berry has declared that he has no signficant relationships to disclose.
List of Design Committee Members: Authors: Marc C. Levesque, MD, PhD, and E. William St. Clair, MD Activity Objectives 1. To understand the rationale for B cell–targeted therapy in autoimmune diseases. 2. To understand the development and differentiation of B cell lineage. 3. To understand the mechanisms of action of B cell–directed antibodies. Recognition of Commercial Support: This CME activity has not received external commercial support. Disclosure of Significant Relationships with Relevant Commercial Companies/Organizations: Marc C. Levesque has consulting arrangements with Genentech; has received research support from the National Institutes of Health, Genentech, and Amgen; has served as an expert witness for Merck; and has served as a member of the Arthritis Foundation. E. William St. Clair has consulting arrangements with Biogen Idec, Genentech, Bristol Myers Squibb, Novartis, Human Genome Sciences, Medimmune, and Synovex; has received research support from the National Institutes of Health, Genentech, and Amgen; and has been a part of ACR Research and Education Board of Directors.
30A January 2008
J ALLERGY CLIN IMMUNOL